Use of SHROOM3 in chronic kidney disease and chronic allograft nephropathy
A method for identifying the risk of developing Chronic Allograft Nephropathy (CAN) in a patient that received a kidney transplant from a donor which comprises identifying the race of the donor; determining the levels of SHROOM 3 expression in a kidney biopsy specimen obtained from the patient at a predetermined time after transplant; comparing the level of SHROOM 3 expression in the biopsy specimen with the levels of SHROOM 3 expression in a control; determining if the level of SHROOM 3 expression in the allograft is significantly higher than in the control, and diagnosing the patient as being at risk for CAN if the level of SHROOM 3 expression in the specimen is significantly higher than in the control.
1. A method for treating a Caucasian allograft recipient that received a kidney allograft from a Caucasian kidney donor and is at an increased risk for developing Chronic Allograft Nephropathy (CAN) comprising the steps of
(a) detecting the presence of an AA allele at the single nucleotide polymorphism (SNP) rs17319721 risk allele in a nucleic acid sample obtained from said Caucasian kidney donor using a nucleic acid-based detection assay, and
(b) identifying said kidney allograft recipient as at an increased risk for developing CAN based on detection of said AA allele at the SNP rs17319721 risk allele detected in said nucleic acid sample obtained from said Caucasian kidney donor, and
(c) administering an immunosuppressive drug to said kidney allograft recipient that received a kidney allograft from said Caucasian donor.
2. A method for treating- a Caucasian kidney allograft recipient who is at an increased risk of developing kidney fibrosis following receipt of a kidney allograft from a Caucasian kidney donor, comprising the steps of:
(a) detecting expression of an AA allele at the single nucleotide polymorphism (SNP) rs 17319721 risk allele using a nucleic acid-based detection assay;
(b) identifying said Caucasian kidney allograft recipient as at an increased risk of developing kidney fibrosis based on the detection of said AA allele at the SNP rs17319721 risk allele in the nucleic acid sample obtained from said Caucasian kidney donor, and
administering an immunosuppressive drug to said kidney allograft recipient.
3. The method of claim 1 further comprising administering an angiotensin converting enzyme inhibitor to said kidney allograft recipient.
4. The method of claim 2 further comprising administering an angiotensin converting enzyme inhibitor to said kidney allograft-recipient.
5. The method of claim 1 wherein said nucleic acid sample comprises a blood sample obtained from said Caucasian kidney donor.
6. The method of claim 1 wherein said nucleic acid sample comprises a biopsy sample obtained from said kidney allograft.
7. The method of claim 2 wherein said nucleic acid sample comprises a blood sample obtained from said Caucasian kidney donor.
8. The method of claim 2 wherein said nucleic acid sample comprises a biopsy sample obtained from said kidney allograft.
9. A method for treating an intended kidney allograft recipient at risk of developing kidney fibrosis following the intended kidney allograft from a Caucasian kidney donor, comprising the steps of:
detecting expression of an AA allele at the single nucleotide polymorphism (SNP) rs 17319721 risk allele in a nucleic acid sample obtained from the Caucasian kidney donor at baseline using a nucleic acid-based detection assay; and
identifying said kidney allograft recipient as being at an increased risk of developing kidney fibrosis following the intended kidney allograft from a Caucasian kidney donor in the event that said AA allele at the SNP rs17319721 risk allele is detected in the nucleic acid sample obtained from said Caucasian kidney donor, and
administering an immunosuppressive drug to said kidney allograft recipient that received a kidney allograft from said Caucasian donor.